A phase I study of DMOT4039A, an antibody-drug conjugate (ADC) targeting mesothelin (MSLN), in patients (pts) with unresectable pancreatic (PC) or piatinum-resistant ovarian cancer (OC)

Colin D. Weekes, Laetitia E. Lamberts, Mitesh J. Borad, Johannes Voortman, Robert R. McWilliams, Jennifer Robinson Diamond, Elisabeth De Vries, Henk M. W. Verheul, Christopher Hanyoung Lieu, Huibin Yue, Yulei Wang, Suzie Scales, Divya Samineni, Katie Wood, Flavia Brunstein, Daniel J. Maslyar, George P. Kim

Research output: Contribution to journalMeeting AbstractAcademic

Original languageEnglish
JournalJournal of clinical oncology
Issue number15
Publication statusPublished - 20 May 2014

Cite this